Mediolanum International Funds Ltd Purchases 14,795 Shares of Zoetis Inc. $ZTS

Mediolanum International Funds Ltd increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 211,304 shares of the company’s stock after purchasing an additional 14,795 shares during the period. Mediolanum International Funds Ltd’s holdings in Zoetis were worth $32,999,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nova Wealth Management Inc. bought a new stake in Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $27,000. Saudi Central Bank bought a new stake in shares of Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC raised its holdings in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.0%

Shares of Zoetis stock opened at $115.86 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. The company has a market capitalization of $51.06 billion, a price-to-earnings ratio of 19.94, a PEG ratio of 2.31 and a beta of 0.90. The firm’s 50-day moving average price is $138.28 and its two-hundred day moving average price is $150.42.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s payout ratio is 33.67%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. UBS Group dropped their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Stifel Nicolaus reduced their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday. Morgan Stanley lowered their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Finally, KeyCorp began coverage on shares of Zoetis in a research report on Thursday. They issued a “hold” rating for the company. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.